Fresenius Medical Care, the world’s largest provider of dialysis products and services, is aware that patient data from some of the company’s dialysis centers in Serbia has been published by unauthorized persons.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today successfully placed bonds in two tranches with an aggregate volume of €1.25 billion.
9% revenue increase supported by growth in all regions; Positive earnings growth despite negative impact from COVID-19 pandemic; Solid cash-flow development; Financial targets for FY2020 confirmed
Fresenius Medical Care, the world’s leading provider of dialysis products and services, has released an advisory calling for clinical care principles on access to be upheld for patients with advanced chronic kidney disease if a surge in COVID-19 infections overwhelms the available supply of facilities, caregivers and ventilators.
Fresenius Medical Care North America has announced a collaboration with DaVita Inc. and other dialysis providers in response to COVID-19, which aims to support the broader kidney care community in the United States by offering isolation capacity for dialysis patients who are or may be COVID-19 positive.
Fresenius Medical Care, the world’s leading provider of dialysis products and services, postpones its 2020 Annual General Meeting, which was scheduled for May 19, to a later date this year due to the coronavirus pandemic.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, has filed the annual report 2019 on form 20-F with the U.S. Securities and Exchange Commission (SEC).
Solid Q4 performance; Full year guidance achieved; Investments in home dialysis and growth markets as planned; Cost optimization initiatives as planned; 23rd dividend increase proposed; Outlook 2020 confirmed
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today successfully placed bonds in three tranches with an aggregate volume of €1.75 billion.
